Nasdaq

XBiotech Inc.

Pharmaceutical PreparationsCIK 0001626878Austin, TexasFilings at SEC EDGAR

At a glance

Most recent filing on October 28, 2026 — a grant by Simard Jan-Paul on Oct 26, 2026.

We hold 2 Form 4 lines, going back to October 28, 2026.

Insider trades

All 2 shown

This page is free to read, and it stops after 2 rows. Everything we currently hold fits inside that, so nothing is being held back here today. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Simard Jan-Paul Co-Chief Executive Officer
2,000,000 sharesGrant
TradedOct 26, 2026FiledOct 28, 2026
SIMARD JOHN Director, 10% owner
$711,251Open-market buy
TradedOct 26, 2026FiledOct 28, 2026

CEO pay

What the company reported for its principal executive officer, usually the CEO, in the pay-versus-performance table of its proxy statement. The total counts shares and options at their value on the day they were granted. Actually paid counts them at the change in their value during the year, so it can be far higher or lower than the total, and negative. A dash means the company reported no amount.

Principal executive officer, fiscal year ended Dec 31, 2025: total $30,102,697, actually paid $27,102,297. First reported Oct 2, 2026.

Earlier fiscal years are part of the subscription.